| WB | 1/500-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | G15; H37; RMB5; LUCA15 |
| WB Predicted band size | 92 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human RBM5 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于RBM5抗体的模拟参考文献示例(仅供学术参考，非真实文献)：
---
1. **文献名称**: *RBM5 Expression in Lung Cancer: Prognostic Implications and Antibody Validation*
**作者**: Sutherland LC, et al.
**摘要**: 本研究通过免疫组化(IHC)和Western blot验证了RBM5抗体在肺癌组织中的特异性，发现RBM5低表达与患者预后不良相关，提示其作为潜在生物标志物的价值。
2. **文献名称**: *RBM5 Regulates Apoptosis via Interaction with Bcl-xL: Insights from Antibody-Based Functional Assays*
**作者**: Rintala-Maki ND, et al.
**摘要**: 利用RBM5特异性抗体进行免疫共沉淀(Co-IP)和流式细胞术分析，揭示RBM5通过结合Bcl-xL调控细胞凋亡，为癌症治疗靶点研究提供依据。
3. **文献名称**: *Epigenetic Silencing of RBM5 in Breast Cancer: Validation by qRT-PCR and Immunohistochemistry*
**作者**: Oh JJ, et al.
**摘要**: 通过qRT-PCR和RBM5抗体驱动的免疫组化分析，证实乳腺癌中RBM5的表观遗传沉默，其表达缺失与肿瘤侵袭性增强相关。
4. **文献名称**: *RBM5 as a Tumor Suppressor: Antibody Development and Clinical Correlation in Colorectal Cancer*
**作者**: Edamatsu H, et al.
**摘要**: 开发了一种高特异性RBM5单克隆抗体，并应用于结直肠癌组织微阵列分析，证明RBM5表达降低与肿瘤分期进展及转移风险增加显著相关。
---
**注意**：以上文献为示例性质，实际研究需通过PubMed、Web of Science等平台检索真实文献(关键词：RBM5 antibody, immunohistochemistry, cancer)。
The RNA-binding motif protein 5 (RBM5) is a member of the RNA-binding protein family, known for its role in post-transcriptional gene regulation, particularly in mRNA splicing, stability, and translation. RBM5 contains conserved RNA recognition motifs (RRMs) and a zinc finger domain, enabling interactions with RNA and protein partners. It is implicated in critical cellular processes, including cell cycle control, apoptosis, and differentiation. Research highlights its tumor-suppressive functions, as RBM5 expression is frequently downregulated in cancers such as lung, breast, and prostate cancer. It modulates alternative splicing of apoptosis-related genes (e.g., Bcl-x, FAS) and regulates signaling pathways like the p53 and MAPK cascades, influencing cancer progression and therapy resistance.
RBM5 antibodies are essential tools for studying its expression, localization, and molecular interactions. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunoprecipitation (IP) to investigate RBM5's role in normal physiology and disease. Commercially available antibodies target specific epitopes within its N-terminal or C-terminal regions, with validation across human and model organism tissues. Dysregulation of RBM5 has also been linked to neurological disorders, expanding its research relevance. However, challenges remain in understanding its isoform-specific functions and regulatory networks. Ongoing studies aim to clarify RBM5's potential as a diagnostic biomarker or therapeutic target, particularly in precision oncology.
×
